New book by Larry Connors Click here Improve your trading - See how
The acquisition includes products in the U.S., Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge.
As part of the deal, Boehringer Ingelheim will acquire the Duramune(R) line of vaccines for dogs, the Fel-O-Vax(R) line of vaccines for cats, and the Rabvac(R) line of rabies vaccines manufactured and sold in the U.S., Canada and Australia. In addition, a portfolio of pet and equine pharmaceutical products currently sold in the U.S. is also included in the deal. The company will also acquire cattle vaccines in the U.S. and Canada including the Triangle(R), Pyramid(R), and Presponse(R) vaccine lines. Pharmaceutical products being acquired include Cydectin(R) (moxidectin) for cattle and sheep as well as Polyflex(R) (ampicillin sodium). The dairy portfolio includes the key brands Today(R) and Tomorrow(R). Several Canadian swine vaccines are included in the acquisition as are some cattle vaccines sold in Europe and South Africa.
Announcement (September 22, 2009):
Boehringer Ingelheim has entered into an agreement to acquire certain assets of Wyeth Pharmaceutical's Fort Dodge Animal Health business.
Update on August 5, 2009:
According to Reuters, Boehringer Ingelheim GmbH is the front-runner to acquire certain Fort Dodge animal health assets from Wyeth.
Wyeth is not selling its entire Fort Dodge business, just certain assets within the unit that are valued at approximately $400 million to $500 million.
Rumor (July 8, 2009):
According to Dow Jones, Boehringer Ingelheim is contemplated to be one of the potential bidders to acquire certain Fort Dodge animal health assets from Wyeth.
Reportedly, Sanofi-Aventis S.A. and Novartis AG are also contemplated to be in the race to acquire certain Fort Dodge animal health assets from Wyeth.
Deal Type Acquisition Sub-Category Asset Purchase Deal Status Completed: 2009-10-26
Deal Participants
Target (Company) Wyeth - Fort Dodge Animal Health Assets Acquirer (Company) Boehringer Ingelheim GmbH Vendor (Company) Wyeth (formerly American Home Products Corporation)
Deal Rationale
The assets will significantly increase the size of Boehringer Ingelheim's companion animal and cattle portfolios and strengthens its position as a leading vaccine supplier. The products included in this acquisition complement Boehringer Ingelheim's already strong product lines and help to broaden its innovation base across more species and boost its global pipeline.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
